GSK’s RSV Vaccine Arexvy protects adults aged 50 to 59, early results show by Editor | Oct 26, 2023 | LATEST NEWS, Pharmaceuticals & Manufacturing, Science, Technology & Research, WORLD NEWS | 0 UK—GlaxoSmithKline (GSK) has released positive preliminary results from a late-stage study of its... Read More